Incannex Healthcare Inc ADR (IXHL) Stock Price, Quote & News

Company Profile

Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety diso...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 61 4 0984 0786

Website: www.incannex.com

Address:

8 Century Circuit, Suite 105 Norwest, Sydney, Australia

RollTheDice369 Mar. 16 at 10:43 AM

$IXHL Eli Lilly, Jazz or RMD. Hmm

0 · Reply

Bullish449 Mar. 16 at 10:28 AM

$IXHL does that mean he is leaving company. If true then it will be very bullish more than fda phase 3 approval for IXHL drug.

1 · Reply

Michaelthoaicaonguyen Mar. 16 at 10:26 AM

$IXHL don’t you hate it when you try to prove your bull is wrong but he’s right yall. Doing my DD , not to shame Mr. Smith or discredit him (I dare not for I am an amateur) but to understand the risk that comes with the reward. Hate it when he’s right. This way i can formulate how I would invest in this stock moving forward. Thank you Mr. Smith for reminding me about ELOC. Ughhh😩😩😩

0 · Reply

Michaelthoaicaonguyen Mar. 16 at 10:13 AM

$IXHL good morning bulls.

1 · Reply

IldijanaMM Mar. 16 at 10:10 AM

$IXHL Market cap 38M$ and 80M$ in cash 😏 Assets are worth minus right now 😬

2 · Reply

Michaelthoaicaonguyen Mar. 16 at 10:05 AM

$IXHL ok I’m so scared of ATM that I dreamt about ELOC. Woke up to do some DD on ELOC, not to prover Mr. Smith wrong. Just have confirm his info and soothe my nightmare. The unfortunately after doing my DD, I’m afraid Mr. Smith would s 100% correct. ELOC is still alive and active. I hope he don’t use it for GAD. Fully funded for Reposa but not GAD. First, ELOC is not an ATM but the same purpose is to raise money by adding shares. And if he does I still can’t exit because this was created in 2024. Not a new ATM therefore I have to stay only new ATM then can I’ll leave. This Forehead Faggot, seems to find every reason to hold me and take my money. Don’t use it Joel. Our partner will pay for everything after EOP2 disclosure.

0 · Reply

GoldManStackz Mar. 16 at 7:28 AM

$RMD $IXHL $SPY tf is this trending when there’s been like 4 messages in 2 weeks

1 · Reply

Michaelthoaicaonguyen Mar. 16 at 7:25 AM

$IXHL @Seamlessmingler @s2kfan Mr. Smith have something here folks. I remember ELOC. let just hope he don’t use this before EOP2 and P2 data. Unless Joel really want me to exit my position. I don’t think Mr. Smith is bearish of any kind. Knowing the risks help you with future decisions. I will dig deeper into ELOC when I wake up. Good night again

0 · Reply

Seamlessmingler Mar. 16 at 7:20 AM

$IXHL sorry not the ATM that was closed but...... The ELOC was established in September 2024 via a Purchase Agreement with Arena Business Solutions Global SPC II, Ltd. (an Arena affiliate), providing up to $50 million in potential funding through periodic sales of common stock at the company's discretion over 36 months. It included commitment shares, a warrant, and related registrations (e.g., S-3 filings covering up to 50M+ shares. Company filings and disclosures through early 2026 (e.g., 10-Qs filed in February 2026 and November 2025) still reference the ELOC as in place, describing its terms without indicating termination. No 8-K or other announcements in 2026 mention terminating the ELOC or the related Arena agreements (unlike the ATM, which was explicitly ended on March 11, 2026, via mutual agreement with Curvature and A.G.P.). So the plot thickens?

1 · Reply

Michaelthoaicaonguyen Mar. 16 at 6:47 AM

$IXHL where do you get the 50 million ATM from. Where how? I thought currently they close all ATM. Can some clarify this. If Mr. Smith is right and I always concerned for the GAD funding, if he open a new ATM for GAD we are fucked yall.

1 · Reply

Incannex Stock Slides As $10 Million Capital Raise Funds Next Study For Sleep Apnea Treatment

Mar 12, 2026, 8:05 AM EDT - 3 days ago

Incannex Healthcare Inc. Announces Pricing of $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Feb 25, 2026, 9:20 AM EST - 18 days ago

Incannex Announces Reverse Stock Split

Feb 18, 2026, 6:35 PM EST - 25 days ago

Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 2Q 2026

Jan 29, 2026, 8:00 AM EST - 6 weeks ago

Incannex Healthcare Announces Additional Appointments to Clinical Advisory Board

Jan 22, 2026, 8:00 AM EST - 7 weeks ago

Incannex Healthcare Announces Formation of Clinical Advisory Board for PSX-001 Program

Jan 15, 2026, 8:00 AM EST - 2 months ago

Incannex Healthcare Wins Research and Development Award for Obstructive Sleep Apnea Program in the 2025 Clinical Trials Arena Excellence Awards

Jan 14, 2026, 8:00 AM EST - 2 months ago

Incannex Healthcare Delivers Transformational 2025 Progress and Outlines Well-Funded Outlook for 2026

Dec 3, 2025, 8:00 AM EST - 3 months ago

Incannex Granted FDA Fast Track Designation for IHL-42X in Obstructive Sleep Apnea (OSA)

Nov 20, 2025, 9:34 AM EST - 4 months ago

Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 1Q 2026

Oct 30, 2025, 8:00 AM EDT - 4 months ago

Incannex Provides Shareholder Update Highlighting Clinical Progress, Capital Discipline, and EOY 2025 Strategic Focus

Oct 22, 2025, 8:00 AM EDT - 5 months ago

Incannex Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

Aug 26, 2025, 8:00 AM EDT - 7 months ago

Incannex Reports Positive Results from Phase 2 Clinical Trial of PSX-001 (Psi-GAD) for Generalised Anxiety Disorder

Aug 22, 2025, 8:00 AM EDT - 7 months ago

Incannex Healthcare Authorizes $20 Million Share Repurchase Program

Aug 19, 2025, 4:29 PM EDT - 7 months ago

Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 3Q 2025 - Update

Aug 8, 2025, 8:00 AM EDT - 7 months ago

Incannex Receives Positive Patient-Reported Outcomes and Compelling Phase 2 Efficacy Data for IHL-42X in Obstructive Sleep Apnoea

Jul 31, 2025, 8:00 AM EDT - 8 months ago

Incannex Confirms Strong Cash Position; No Plans or Requirement to Fully Utilise ATM in Near Term

Jul 30, 2025, 10:10 AM EDT - 8 months ago

Nano-Cap Incannex's Sleep Apnea Candidate Shows Effectiveness And Safety In Mid-Stage Trial

Jul 30, 2025, 8:00 AM EDT - 8 months ago

Incannex Reports Positive Topline Results from RePOSA Phase 2 Trial of IHL-42X

Jul 25, 2025, 7:30 AM EDT - 8 months ago

Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Charlene E. Gamaldo

Jun 24, 2025, 7:30 AM EDT - 9 months ago

Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Douglas B. Kirsch

Jun 18, 2025, 7:30 AM EDT - 9 months ago

Incannex achieves key milestone with database lock for RePOSA Phase 2 trial of IHL-42X

Jun 17, 2025, 7:30 AM EDT - 9 months ago

Incannex Healthcare Forms Joint Venture with Mind Medicine Australia to Expand Access to Psychedelic-Assisted Therapy

Jun 12, 2025, 7:30 AM EDT - 9 months ago

Incannex Healthcare Cancels All Outstanding Series A Warrants Following Strategic ATM Execution

Jun 3, 2025, 7:30 AM EDT - 10 months ago

Incannex Healthcare Inc. Expands IHL-42X Clinical Advisory Board with Appointments of Four Industry and Academic Leaders to Advance Obstructive Sleep Apnea (OSA) Program

May 29, 2025, 7:30 AM EDT - 10 months ago

Incannex Healthcare Inc. Advances IHL-42X RePOSA Trial to Phase 3 Following FDA Protocol Clearance

May 28, 2025, 4:21 PM EDT - 10 months ago

Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 3Q 2025

May 28, 2025, 7:00 AM EDT - 10 months ago

Incannex Healthcare Inc. Enters Agreement to Cancel Remaining Series A Warrants, Eliminating Up to 347.2 Million Shares from Potential Dilution Ahead of IHL-42X Phase 2 Topline Results

May 20, 2025, 7:30 AM EDT - 10 months ago

Incannex Healthcare Inc. Executes Strategic Cancellation of 50.4% of Series A Warrants, Significantly Reducing Potential Dilution

May 16, 2025, 9:00 AM EDT - 10 months ago

Incannex Announces Potential Reduction of Up to 50.4% of its Series A Warrants

May 15, 2025, 8:00 AM EDT - 10 months ago

Incannex Healthcare Inc. Reports Fiscal Third Quarter 2025 Financial Results and Business Updates

May 14, 2025, 4:14 PM EDT - 10 months ago

Incannex Healthcare (IXHL) Stock Soars Over 800%: What's Going On?

May 14, 2025, 8:00 AM EDT - 10 months ago

Incannex Healthcare Inc. Provides Clinical Program Update on IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)

Apr 3, 2025, 7:30 AM EDT - 1 year ago

Incannex Healthcare Completes Phase 2 Enrollment in RePOSA Phase 2/3 Trial of IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)

Mar 7, 2025, 2:10 PM EST - 1 year ago

Incannex Healthcare Inc. Announces Pricing of $12.5 Million Private Placement Priced at the Market Under Nasdaq Rules

Feb 18, 2025, 5:51 PM EST - 1 year ago

Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 2Q 2025

Feb 14, 2025, 7:30 AM EST - 1 year ago

Incannex Healthcare Inc. Reports Fiscal Second Quarter 2025 Financial Results and Business Updates

Feb 4, 2025, 9:15 AM EST - 1 year ago

Incannex Healthcare Appoints Alison Wimms, Ph.D. to Newly Formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board

Jan 23, 2025, 7:30 AM EST - 1 year ago

Incannex Healthcare Announces Positive Topline Results from Pharmacokinetics (PK) Study of IHL-42X, an Oral Combination Medicine for the Treatment of Obstructive Sleep Apnea

Dec 2, 2024, 4:48 PM EST - 1 year ago

Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 1Q 2025

Nov 14, 2024, 4:05 PM EST - 1 year ago

Incannex Healthcare Inc. Reports Fiscal First Quarter 2025 Financial Results and Business Updates

Oct 24, 2024, 7:30 AM EDT - 1 year ago

Incannex Announces Appointment of Dr. Lou Barbato as Chief Medical Officer

Oct 2, 2024, 4:50 PM EDT - 1 year ago

Stonegate Initiates Coverage on Incannex Healthcare Inc. (IXHL)

Sep 30, 2024, 4:01 PM EDT - 1 year ago

Incannex Healthcare Inc. Reports Fiscal Full Year 2024 Financial Results and Business Updates

Sep 9, 2024, 8:00 AM EDT - 1 year ago

Sleep Apnea Pill: Quantum Research Survey Shows Sleep Apnea Patients Seeking CPAP Alternatives

Aug 5, 2024, 7:30 AM EDT - 1 year ago

FDA Review of PsiGAD2 IND complete; clinical trial for Psilocybin Assisted Psychotherapy in Patients with Generalised Anxiety Disorder to Proceed

Jul 30, 2024, 7:30 AM EDT - 1 year ago

Dosing completed in 115 participant bioavailability/bioequivalence clinical trial for proprietary sleep apnea drug candidate IHL-42X

May 30, 2024, 7:30 AM EDT - 1 year ago

Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea

May 7, 2024, 7:30 AM EDT - 2 years ago

Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-O for treatment of opioid use disorder

May 1, 2024, 2:33 PM EDT - 2 years ago

Stonegate Healthcare Partners Releases Report on Potentially Transformative Therapies for Generalized Anxiety Disorder (GAD)

RollTheDice369 Mar. 16 at 10:43 AM

$IXHL Eli Lilly, Jazz or RMD. Hmm

0 · Reply

Bullish449 Mar. 16 at 10:28 AM

$IXHL does that mean he is leaving company. If true then it will be very bullish more than fda phase 3 approval for IXHL drug.

1 · Reply

Michaelthoaicaonguyen Mar. 16 at 10:26 AM

0 · Reply

Michaelthoaicaonguyen Mar. 16 at 10:13 AM

$IXHL good morning bulls.

1 · Reply

IldijanaMM Mar. 16 at 10:10 AM

$IXHL Market cap 38M$ and 80M$ in cash 😏 Assets are worth minus right now 😬

2 · Reply

Michaelthoaicaonguyen Mar. 16 at 10:05 AM

0 · Reply

GoldManStackz Mar. 16 at 7:28 AM

$RMD $IXHL $SPY tf is this trending when there’s been like 4 messages in 2 weeks

1 · Reply

Michaelthoaicaonguyen Mar. 16 at 7:25 AM

0 · Reply

Seamlessmingler Mar. 16 at 7:20 AM

1 · Reply

Michaelthoaicaonguyen Mar. 16 at 6:47 AM

1 · Reply

Seamlessmingler Mar. 16 at 6:25 AM

$IXHL This dreaming study will enroll new patients and possibility of a new set of super responsive OR not responsive. Still imo as risky as P2 reposa study They had 9 months to prepare to tell us this was happening Even given it a name. Was likely the plan all along but if you were honest and said 2028 instead of 2026 then you would be broke. Basicly Dubai salesman playing pharma guy on our dime while he creams it for years Again whats the reason for moving offices to dubai? Our whole program is USA based Sorry but this don't add up

3 · Reply

modrica3 Mar. 16 at 5:36 AM

$IXHL b-a-l-o-n-e-y

1 · Reply

Seamlessmingler Mar. 16 at 5:31 AM

$IXHL new ATM inbound. This company needs cash for 675 , PSI GAD so watch this space. Just before dreamzz topline data release they will file another ATM and pump it into that news. Just rember they still have a ATM 50m left with arena finance the original sodomisers of the SP. Theres 2 ATM i only see one closed ???

2 · Reply

PeePeePantsCity Mar. 16 at 5:12 AM

$IXHL Maybe pooped on the shit stock scanner!💩

0 · Reply

RogueFF7 Mar. 16 at 4:33 AM

$IXHL post 2 of 2 M&A treatment of warrants. If a buyer offers $14 per share for the 12 million outstanding shares, they also need to address the 2 million outstanding warrants. The Black-Scholes formula can value the warrants, but likely below $14 per warrant—possibly around $7.50–$9 depending on strike price, stock volatility, and time to expiration. In a buyout, the warrants could be cashed out, exercised and included in the acquisition, or treated similarly to shares so holders receive the same per-share offer.

0 · Reply

RogueFF7 Mar. 16 at 4:24 AM

$IXHL ok. I think I have an update. I’ve been reading comments regarding the cashless component of the warrants… and M&A treatment for warrants. Common Warrants ($6.50 exercise price) — This Is the Key One: The cashless exercise provision for Common Warrants is conditional — a holder may only elect cashless exercise if, at the time of exercise, there is no effective registration statement registering the Common Warrant shares. This is a meaningfully better structure than many retail investors fear. It means: ∙ As long as Incannex maintains an effective S-3 registration statement (which they have — a $150M shelf), warrant holders must exercise for cash to get shares ∙ Cashless exercise is only a fallback if that registration lapses or becomes ineffective ∙ The $13 million in potential additional proceeds is therefore genuinely achievable as long as the S3 remains Post 1 of 2.

0 · Reply

Michaelthoaicaonguyen Mar. 16 at 4:23 AM

$IXHL no he didn’t it’s still on LinkedIn Why lie about something when you know people can prove you wrong.

1 · Reply

reggieoneil Mar. 16 at 4:18 AM

$IXHL Joel deleted his LinkedIn

0 · Reply

Michaelthoaicaonguyen Mar. 16 at 4:15 AM

$IXHL bulls get some rest. Rest your mind. Risks are gone for now. See yall tomorrow morning.

0 · Reply

Michaelthoaicaonguyen Mar. 16 at 4:06 AM

$IXHL I was just thinking about GAD, Kris brought this PTSD topic up. Again going back to ATM. We all know we have money for Reposa including funds for DReamzz. Now do we have money for GAD? If Forehead open new ATM for GAD, we’re fuck. So let’s hope with all speculation on partnership and merger, that partner will cover both Reposa and GAD. So bulls say it with me “No ATM”

1 · Reply

krispen Mar. 16 at 3:57 AM

$IXHL For what it is worth in the collective Hope Chest of this Community… this was posted earlier tonight elsewhere… 👀 Remember, APNEA is just ONE of the conditions and active therapies “in the hunt”! 😎

0 · Reply

StanleyYoungz Mar. 16 at 3:46 AM

What I will be watching tomorrow for entry: $IPM $IXHL $OPEN.X $CXAI and $STAK

0 · Reply

Market Cap	38.78M
Revenue (ttm)	90,000.00
Net Income (ttm)	-46.89M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-52,100.00%
Debt to Equity Ratio	0.00

Volume	1,215,300
Avg Vol	426,611
Day's Range	N/A - N/A
Shares Out	11.93M
Stochastic %K	11%
Beta	7.55
Analysts	Hold
Price Target	N/A